FactSet: The Selling Reset the Price, Not the Moat Question—Sept. 30 Decides

FactSet (NYSE: FDS) just filed something that is easy to read too far into. In late August, the financial-data provider amended its credit agreement, extending its term loan to 2029, pushing its revolving facility out to August 2031, and raising the revolver from $1 billion to $1.5 billion. Some takes on the filing claim the stock now sits "about 2% overvalued," as if a bank term sheet could price a business. It cannot. A financing amendment tells you almost nothing about what FactSet is worth; it tells you only that the company wanted more borrowing room at better terms. The numbers that actually set the price — growth, margins, the durability of the moat, the cost of capital — are not in the filing. So before accepting any fine-grained fair-value read off this document, it is worth laying down what the amendment really does, and then what it does not say.

What the credit filing actually confirms

The amendment is balance-sheet housekeeping with a purpose. FactSet, working with PNC as administrative agent, extended the maturity of its $375 million senior unsecured term loan to August 28, 2029, removed the term loan's scheduled amortization, and enlarged its revolver to $1.5 billion out to August 2031. The stated aim is financial flexibility — room to integrate recent acquisitions and to keep investing in GenAI products while managing higher cloud costs, without tripping over near-term principal payments.

That reads as a company choosing to fund its scale-up with cheap debt rather than stress-test its cash. The numbers back the choice. FactSet held roughly $288 million in cash against $2.16 billion in total debt, or about $1.1 billion of net debt. Against trailing free cash flow of roughly $708 million, that is a modest load — around 1.5 times FCF. Nothing about the credit line signals distress.

The more consequential read is what the filing protects. FactSet has paid a dividend for 24 straight years and raised it for 17, and the trailing payout runs about 37% of earnings. With free cash flow of roughly $708 million and a dividend bill in the neighborhood of $165 million a year, the payout is covered more than four times over. The larger revolver and stretched maturities are an insurance policy for that dividend and for continued buybacks while the company spends through an AI-heavy investment phase. If you are an income-oriented investor, the credit amendment quietly reassures: the cash to honor the dividend is there, and leverage is not crowding it out.

The real valuation argument is a moat, not a maturity date

This is where the "2%" framing does the most harm, because it treats the stock as fairly priced when the genuine controversy is unresolved. To see why, you have to put the selloff next to the peer group. FactSet has fallen about 29% from its 52-week high near $365 — including a sharp 17% drop over the past five trading days — and now trades at roughly 16 times trailing earnings and about 11 times EV/EBITDA. Its closest data-and-index peers are dramatically more expensive: Moody's at about 21 times EV/EBITDA, S&P Global near 16 times, and MSCI around 24 times. FactSet, in other words, is being priced at a roughly 40% discount to comparable businesses on this basis.

Discounts that large are not handed out for nothing. The strongest bear fact is that Morningstar — one of the few independent voices that used to grant FactSet a "narrow" moat — stripped that rating to "none" in early March 2026, cut its fair-value estimate from $360 to $275, and raised the cost of equity it uses from 7.5% to 9%. Its reasoning is blunt: outside the CUSIP securities-identifier business (which is moaty but only about 15% of operating profit), FactSet's data and workflow products no longer look proprietary once generative AI lets competitors replicate them cheaply. That is a structural point, not a cyclical one. It says the wide-moat premise that once justified a premium multiple may be gone.

The counterweight is that the operating business has not deteriorated nearly as fast as the price. Revenue is still growing — up roughly 6.6% year over year — margins remain high, free cash flow grew about 23% from the prior year, and management has been nudging fiscal 2026 EPS guidance higher, to a midpoint near $17.50. That is a company slowing to high-single-digit growth, not one in decline. On the current fiscal-year number, the stock trades near 15 times earnings — a low-teens multiple for a 24-year dividend grower with high free-cash-flow margins. The reset in price has run well ahead of the reset in the business, which is exactly the configuration that can make a selloff overdone.

The September 30 test, and what would change the read

Whether that discount is a gift or a trap will not be settled by any credit filing; it will be settled by the next earnings report. FactSet's fiscal fourth quarter — and the fiscal 2027 outlook it brings — is due around September 30, and it lands just weeks after the shares' slide. That print is the nearest falsifiable fork. If growth holds near mid-single digits, margins stop eroding from AI spending, and management shows GenAI converting into paid demand and bookings rather than just feature launches, then the low multiple starts to look like fear repricing a still-cash-generative business. If, instead, the AI investment keeps compressing margins with no revenue proof and growth slips toward low single digits, the discount is doing its job — reflecting a moat that has genuinely narrowed.

For a retail investor, the useful distinction is between business quality and stock quality, which here point in different directions. The dividend is safe, the balance sheet is flexible, and free cash flow is real — those are facts the credit agreement supports and that cushion the downside near this price. But "cheap" in a stock whose moat was just downgraded to none is cheap for a reason, not by accident. The reset has improved the risk-reward for patient income-and-value buyers; it has not erased the need for September's evidence. That makes this a hold-and-watch with a favorable tilt — buy the discount only if you can tolerate the moat question staying open until the next report answers it.